Epigenetics and Cancer
Organizer(s): Tony Kouzarides and Kristian HelinDate: January 25 - 30, 2015
Location: Keystone Resort, Keystone, CO, USA
Cancer epigenetics is a new and rapidly developing area of research. This results from the discovery that many epigenetic regulators (chromatin modifying enzymes, modification-reading proteins and chromatin-remodeling activities) are found mutated in cancers and has led to the recent approval of cancer drugs targeting epigenetic enzymes. The meeting aims to bring together scientists who are interested in understanding the connections between basic epigenetic pathways and the process of cancer. One aspect of the meeting will highlight the mechanisms by which epigenetic pathways control various biological processes. Information will be presented on chromatin and DNA modifications, chromatin complexes and ncRNAs. A second aspect will revolve around the connections between epigenetic pathways and cancer. This section will highlight genetic and epigenetic changes that take place during oncogenesis and efforts to counteract cancer with small molecule inhibitors against epigenetic regulators. The hope is to provide a forum for the interchange of information and know-how between the two converging fields of cancer research and epigenetics.
Scholarship Deadline: September 30 2014
Discounted Abstract Deadline: September 30 2014
Abstract Deadline: October 23 2014
Discounted Registration Deadline: November 24 2014
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We gratefully acknowledge the generous grant for this conference provided by:National Cancer Institute (NCI)
Grant No. 1R13CA189412-01
Funding for this conference was made possible (in part) by 1R13CA189412-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.